Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,623 across all filing types
Latest filing 2025-11-13 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-11-13 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-11-13 English
PROXY FORM FOR USE AT THE 2025 THIRD EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Proxy Form' for the 2025 Third Extraordinary General Meeting of RemeGen Co., Ltd. It provides shareholders with the ability to appoint a proxy to vote on specific resolutions (related party transactions and governance policy amendments). According to the filing definitions, documents used to request votes and provide information for meetings are classified as Proxy Solicitation & Information Statements (PSI).
2025-11-13 English
NOTICE OF 2025 THIRD EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of 2025 Third Extraordinary General Meeting' issued by RemeGen Co., Ltd. It outlines the date, time, location, and the specific resolutions (ordinary resolutions) to be voted upon by shareholders. This document is a classic proxy solicitation material sent to shareholders to inform them of an upcoming meeting and request their participation/votes, which falls under the Proxy Solicitation & Information Statement category.
2025-11-13 English
(1) DAY-TO-DAY RELATED PARTY TRANSACTIONS FOR THE YEARS 2026 TO 2028 (2) PROPOSED AMENDMENTS TO GOVERNANCE POLICIES AND NOTICE OF 2025 THIRD EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a circular issued by RemeGen Co., Ltd. to its shareholders. It contains detailed information regarding proposed related party transactions and amendments to governance policies, and it explicitly includes a 'Notice of 2025 Third Extraordinary General Meeting' (EGM). Such documents, which provide information to shareholders to solicit their votes on specific proposals at an upcoming meeting, are classified as Proxy Solicitation & Information Statements.
2025-11-13 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-11-12 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.